Search
Pimozide
go.drugbank.com/drugs/DB01100ApprovedA diphenylbutylpiperidine that is effective as an antipsychotic agent and as an alternative to haloperidol for the suppression of vocal and motor tics in patients with Tourette syndrome.
Glymidine
go.drugbank.com/drugs/DB01382ApprovedIt is used for the concomitant use with insulin for the treatment of noninsulin-dependent (type 2) diabetes mellitus.
Plumbagin
go.drugbank.com/drugs/DB17048InvestigationalPlumbagin is a compound investigated for its anticancer activity. It has been found that it inactivates the Akt/NF-kB, MMP-9 and VEGF pathways.[A253102]
Categories: Hormonal Contraceptives for Systemic Use, Compounds used in a research, industrial, or household settingZK-93423
go.drugbank.com/drugs/DB17063ExperimentalZK-93423 is a beta-carboline with muscle relaxant activity with agonistic properties at the benzodiazepine receptor.[A253172]
Navafenterol
go.drugbank.com/drugs/DB19195InvestigationalNavafenterol is under investigation in clinical trial NCT02971293 (Efficacy, Pharmacokinetics (PK), Safety and Tolerability Study of Inhaled AZD8871).
Eplerenone
go.drugbank.com/drugs/DB00700ApprovedInvestigationalEplerenone, an aldosterone receptor antagonist similar to spironolactone, has been shown to produce sustained increases in plasma renin and serum aldosterone, consistent with inhibition of the negative regulatory feedback of aldosterone ...
Categories: Antihypertensive Agents Indicated for HypertensionTrichloroethylene
go.drugbank.com/drugs/DB13323ApprovedEnvironmental exposure, particularly groundwater and drinking water contamination from industrial discharge, is a major concern for human health and has been the subject of numerous incidents and lawsuits
Categories: Compounds used in a research, industrial, or household settingDezocine
go.drugbank.com/drugs/DB01209ApprovedInvestigationalDezocine is a partial opiate drug and is used for pain management.
Elotuzumab
go.drugbank.com/drugs/DB06317ApprovedInvestigationalElotuzumab has a theoretical mass of 148.1 kDa for the intact antibody. Elotuzumab was approved on November 30, 2015 by the U.S. Food and Drug Administration. … Elotuzumab is a humanized IgG1 (Immunoglobulin G) monoclonal antibody indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received